Pfizer Reports 15% Decrease in Patient Enrollment in Phase 3 Ulcerative Colitis Trial; Enrollment Drops From 912 to 772 Patients; Trial Active But Not Recruiting; Primary Completion Date Revised to July 20, 2026
Portfolio Pulse from Benzinga Newsdesk
Pfizer reports a 15% decrease in patient enrollment in its Phase 3 ulcerative colitis trial, with enrollment dropping from 912 to 772 patients. The trial is active but not recruiting, and the primary completion date has been revised to July 20, 2026.
June 26, 2024 | 5:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pfizer has reported a 15% decrease in patient enrollment for its Phase 3 ulcerative colitis trial, with the number of patients dropping from 912 to 772. The trial remains active but is not recruiting, and the primary completion date has been pushed to July 20, 2026.
The decrease in patient enrollment and the delay in the primary completion date could be seen as setbacks for Pfizer's Phase 3 ulcerative colitis trial. This may lead to negative sentiment among investors, potentially impacting the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100